NCT07942168: Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine Leiomyosarcoma
- State
- Under way
- Phase
- Phase 2
- People
- 100 planned
- Started
- 24 Jan 2023
- Primary completion
- Jan 2027
- Arms
- Doxorubicin+Dacarbazine
- Results
- None posted
- 24 Jan 2023: Trial started
- 17 Nov 2026: Trial registered